General rights Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. 
Introduction
Glaucoma is a leading cause of global blindness, affecting 64·3 million people worldwide in 2013, of whom a sixth dwell in China. 1, 2 Nearly half of all people with primary angle closure (PAC) glaucoma (PACG) are of Chinese descent. 3 Although glaucoma can progress to blindness, it is generally asymptomatic in its early stages, when treat ment is most effective. This makes early detec tion crucial to reduce the risks of visual impairment. 4 Screening programmes might be of particular value in rural settings, where population studies suggest that less than 50% of cases of PACG and less than 10% of cases of primary open angle glaucoma (POAG) are diagnosed. 5 Among those who are diagnosed, glaucoma has already caused severe damage in the majority. 6 However, several studies have reported that populationbased glaucoma screening programmes are not costeffective in high income countries such as the UK 7, 8 and Finland. 9 We believe that glaucoma screening might be cost effective in a Chinese setting for two reasons. First, when compared with other ethnic groups, people of Chinese descent have a two to four times higher prevalence of PACG. 10 The risk of blindness at diagnosis is up to four times higher for PACG than for POAG, which is the more common type of glaucoma among those of European descent. 11 Second, screening is likely to be less expensive in China, due in large part to lower labour costs as compared with highincome countries. 12 To the best of our knowledge, no studies have investigated whether populationbased glaucoma screening is cost effective in China. The only costeffectiveness study 13 of glaucoma screening in an Asian population found that screening is highly costeffective in India. However, a onetime decision analysis was used, which failed to capture the complexity of glaucoma progression in a temporally explicit fashion, and applicability of this result to the population of China is clearly uncertain due to differences in disease profile and healthcare systems in the two countries.
To fill this evidence gap, we aim to provide evidence based policy recommendations by building a compre hensive and dynamic decisionanalytic Markov model incorporating the transition between various disease stages across time and providing for a robust estimate of the costeffectiveness of population screening for glaucoma in China. This model is informed by a large number of glaucoma prevalence studies done in China and includes screening and treatment costs obtained from an actual glaucoma screening programme and a tertiary referral eye hospital in China. For illustrative purposes, we analysed rural and urban settings separately because they are expected to differ in terms of glaucoma prevalence 14, 15 and access to and compliance 16 with health treatments.
Methods

Model overview
TreeAge Pro (TreeAge Software; Williamstown, MA, USA) was used to build Markov models monitoring the transition between discrete health states and the effects of prescribed interventions on transition probabilities. Three Markov models were built to describe separate screening for PACG and POAG and simultaneous screening for both conditions together (appendix). The latter is the most likely screening scenario but we felt it would be useful to understand the separate effects of the two diseases on combined screening, as approaches to screening differ somewhat. Analysing the two disease processes separately provides additional information potentially relevant to other lowresource settings where only one condition (such as POAG for African and Africa derived populations) prevails. However, we acknowledge that there are additional benefits that arise as a result of screening both diseases; therefore, there might be some underestimation of costeffectiveness in the separate screening scenarios. A cohort of individuals was followed in the model from age 50 years through a total of 30 1year Markov cycles. 17 Individuals were allowed to enter as healthy (free from glaucoma) or unhealthy (affected by glaucoma) and could transition to death from any health state. The Markov model for POAG was based on the International Society of Geographical and Epidemiologic Ophthalmology (ISGEO) glaucoma classification, which comprises five stages in addition to normal vision: mild POAG, moderate POAG, severe POAG, POAGrelated unilateral blindness, and POAGrelated bilateral blindness. 18 Each stage has a probability of progression to the next stage, but due to the nature of the disease, the model does not permit regression to an earlier stage even with treatment. The ISGEO classi fication of PACG was used, also
Research in context
Evidence before this study PubMed, MEDLINE, CNKI, and Embase were searched for cost-effectiveness studies of glaucoma screening published in English or Chinese up to Oct 1, 2018, using the terms "glaucoma" AND "screening" OR "detection" AND "economic modelling" OR "cost-effectiveness" OR "cost-benefit" OR "cost-utility". Our search identified eight studies. A 2008 systematic review identified four studies on the cost-effectiveness of glaucoma screening published before 2005 and concluded that all these studies featured methodological weaknesses and outdated screening technology and treatments, providing insufficient evidence on which to base policy recommendations. The studies we identified published from 2005 onwards included studies in the UK, the USA, and Finland, which focused on screening solely for primary open angle glaucoma (POAG), the most prevalent type of glaucoma in these countries. These studies reported that population-based glaucoma screening programmes are not cost-effective in these high-income countries. The only cost-effectiveness study of glaucoma screening in an Asian population found that screening is highly cost-effective in India. However, a one-time decision analysis was used, which failed to capture the complexity of glaucoma progression in a temporally explicit fashion.
Added value of this study
The scenario of combined primary angle closure glaucoma (PACG) and POAG screening is likely to be cost-effective in the rural setting (incremental cost-effectiveness ratio US$1280, 95% CI −58 to 7940; incremental cost-utility ratio $569, 95% CI 17 to 4180) and dominates no screening in the urban setting. A total of 246 years (95% CI 63 to 628) of blindness would be avoided for every 100 000 rural residents screened and 1325 years (510 to 2828) for every 100 000 urban residents screened.
Implications of all the available evidence Our finding that glaucoma screening is cost-effective in a large country like China could be of great importance to policy makers and programme planners. Previous conclusions that glaucoma screening is not cost-effective have been based on assumptions that apply more to high-resource settings-where most such research has been done-than low-income and middle-income countries such as China. This novel finding in China might result from a combination of lower screening costs and higher risk of eventual blindness in the absence of such programmes in the Chinese setting compared with high-income countries. It is also likely that the greater cost-effectiveness of screening for PACG, far more prevalent in China than in European-derived populations, plays an important role.
See Online for appendix encompassing five stages besides normal vision: PAC suspect, PAC, PACG without blindness, PACGrelated unilateral blindness, and PACGrelated bilateral blindness. 18 For both PACG and POAG, the risk of progression from one state to the next was reduced by various types of treatment, with the amplitude of reduction based on available published data.
Glaucoma prevalence
Prevalence studies specific to China have typically reported separate prevalence for POAG and PACG. We reviewed populationbased studies on glaucoma preva lence done among Chinese populations by searching PubMed, MEDLINE, and Embase for articles published in English appearing after the initiation of the ISGEO diagnostic criteria in 2002, using the following combined terms: "glaucoma" AND "prevalence" OR "epidemiology" AND "China" OR "Chinese". We identified ten studies, among which seven (five in rural and two in urban settings, comprising a total of 22 070 participants) reported preva lence of PACG and eight (five rural and three urban, comprising 24 598 participants) reported prevalence of POAG (appendix). After appraising them using the frameworks of Boyle 19 and Morris, 20 prevalence data were quantitatively synthesised by means of a randomeffects metaanalysis 21 processed in R version 3.5.1 (appendix). Prevalence of each ISGEO stage of POAG and PACG among people aged 50 years or older was synthesised separately for rural and urban settings. Because of insufficient data, it was inappropriate to provide separate prevalence estimates for bilateral POAG blindness for rural and urban areas and so a single estimate was provided for both. We used data from a glaucoma screening programme of 27 144 participants in Wenzhou, China, 6 that was carried out by a coauthor (YL) between March, 2014, and September, 2015, to estimate the propor tion of patients with POAG with mild disease as 36·8%, moderate disease as 35·9%, and severe disease as 27·3%.
Our metaanalysis of prevalence studies indicated that 49% of people with PACG in rural areas and 74% of those in urban areas had been previously diagnosed and treated, compared with only 7% and 10% of people with POAG (appendix). Based on the assumption that the proportion of people with previously diagnosed POAG would differ by severity, we assumed that 1·8% of rural patients with mild POAG, 3·2% of those with moderate POAG, and 17·9% of those with severe POAG had been treated previously. The comparable figures in the urban setting were 2·6%, 4·9%, and 26·7%, respectively. The percentage of people with asymptomatic stages of PACG (ie, PAC and PAC suspect) being opportunistically diagnosed was assumed to be zero for both rural and urban settings.
Transition probabilities
All transitions from one health state to another take place in a 1year cycle. Whenever possible, data on all relevant parameters were obtained from published studies or data sources specific to China, which we obtained by searching PubMed, MEDLINE, CNKI, and Embase for studies on glaucoma progression published in English or Chinese, using the following combined terms: "glaucoma" AND "incidence" OR "transition" OR "progression" AND "China" OR "Chinese". However, few data are available on the transition probabilities from one stage to the next stage without treatment intervention for Chinese patients with glaucoma. Therefore, these transition probabilities were inferred from studies done in other Asian countries, those having Chinese or closely related populations (such as Mongolia) being preferred (appendix). If Asian data were not available, we used transition probabilities estimated from other regions. In studies where multiyear rather than 1year glaucoma incidence was reported, the 1year incidence was calculated using the formula r = −log(1 − p)/t, where r denotes the 1year incidence and p represents the cumulative incidence over length of interval t. 22 Transition probabilities between stages of glaucoma after medical treatments were also based on published studies done in Asian countries, such as Mongolia and Singapore, or from unpublished data sources.
Screening and intervention costs
Screening costs were calculated on the basis of the Wenzhou glaucoma screening programme (table 1). 6 These included costs for screening equipment and labour costs for medical personnel. All figures were collected in Chinese yuan but were converted into US dollars at an exchange rate of 6·79 yuan per dollar. The total cost per person for PACG screening was $2·52 (appendix) whereas the figure for POAG was slightly higher at $3·20 due to the need for additional equipment. In China, patients usually pay for medical service at hospitals, the cost of which might be partially reimbursed by medical insurance. We considered the societal costs of medical care, so specific reimbursement rates were not relevant. The costs we used are the amounts charged for medical care provided by the Affiliated Eye Hospital of Wenzhou Medical University-an urban, tertiarylevel centre serving a population of 9 million. A proposed screening programme would reach out to local rural and urban communities, and participants who screen positive after preliminary examinations would be referred to local hospitals for further examination (see appendix for pathways for both organised screening and opportunistic case detection). Following such preliminary community screening, all people with suspected glaucoma were assumed to be referred to local hospitals for a definitive ophthalmic examination including gonioscopy, slitlamp examination of the anterior and posterior segment, fundus photography (Canon CR2 Digital Retinal Camera; Canon, Tokyo, Japan; NIDEK NonMydriatic AFC330 auto fundus cameras; NIDEK, Tokyo, Japan), and auto mated perimetry (Humphrey750i; Carl Zeiss Meditec, Dublin, CA, USA). Those diagnosed with glaucoma were assumed to receive routine clinical care appropriate for the severity of glaucoma. Medications were assumed to be prescribed to patients with mild POAG. Patients with severe or moderate POAG or PACG were assumed to be treated by trabeculectomy, followed by postoperative medications for 6 weeks. Among them, 20% were assumed to fail the surgery and need longterm topical medical therapy. [23] [24] [25] [26] Patients with PAC suspect or PAC were assumed to be treated by laser peripheral iridotomy with 10% of lasertreated patients also needing glaucoma mediation. 27 The costs for the medications and surgeries (table 1) were obtained from the tertiary hospital mentioned above. These costs are controlled by the Chinese Government and vary little between institutions at the same level of the healthcare system. The annual economic burden per bilaterally blind patient used in our model ($8920) consisted of 53·2% direct medical costs, 6·4% direct nonmedical costs, and 40·4% indirect costs. 28 The latter consists of loss of labour resources, loss of productivity among carers (usually family members), and modification costs. We assumed that the total cost for the initial year of bilateral blindness was $8920 and that blind patients incurred only indirect costs (ie, $3600) in subsequent years until death. Because people with unilateral blindness experience fewer productivity losses and require fewer care services compared with people with bilateral blindness, the indirect cost of unilateral blindness was assumed to be 30% of that for bilateral blindness, leading to an estimate of $6380 for the initial year of unilateral blindness and $1080 in subsequent years.
Compliance
Compliance in communitylevel screening was estimated by synthesising compliance data reported in those previous prevalence studies that offered similar free ophthalmologic examinations in China. Our meta analysis showed that 86% of eligible adults from rural areas and 80% from urban areas participated in community screening (table 2) . Compliance with referral to the base hospital for further testing among patients informed they had signs of glaucoma was assumed to be 19% and 57% among rural 16 and urban 6 residents, respectively. Compliance with topical medical therapy was assumed to be 75% and 60% in the urban 39 and rural 38 settings. Acceptance of recommended trabeculectomy surgery among patients diagnosed with PACG was 91% and 80% in the urban 36 and rural 15, 29, 30, 32 settings, respectively. Compliance with laser peripheral iridotomy was assumed to be 78% 27 and 32%, 37 respectively, among urban and rural patients diagnosed with either PAC or PAC suspect.
Screening sensitivity and specificity
Sensitivity (95·3%) and specificity (34·0%) of the proposed outreach community screening for PACG only are based on a screening examination including the van Herick test with a cutoff of no more than 40% anterior chamber depth for the limbal angle, as reported in a populationbased screening programme in China. 43 The sensitivity (64·0%) and specificity (95·0%) for optic nerve photographs are used in modelling the accuracy of POAG screening. 44 In the combined screening scenario, the sensitivity (98·3%) and specificity (32·3%) in the detection of PACG are based on combined sensitivities and specificities of the van Herick test and optic nerve photography.
Utilities and quality-adjusted life-years
To calculate qualityadjusted lifeyears (QALYs), we estimated utilities for each glaucoma stage. Some early stages of glaucoma, such as PAC suspect and PAC, are asymptomatic, so the utilities for the three health states were assumed equal to the full utility of a person free from glaucoma. Utilities were assumed to be 0·80 for people with mild POAG, 0·75 for those with moderate POAG, and 0·71 for those with severe POAG. 7 Following results in the Handan Eye Study, 40 patients with PACG without blindness were assumed to have a utility value of 0·75, whereas patients with unilateral and bilateral blindness were assumed to have utility values of 0·47 and 0·26, respectively. 41 
Other parameters
We used the natural agespecific mortality rates reported by Zhang and Wei. 45 Mortality rates were also allowed to depend on glaucoma severity with increased odds of mortality for people with mild and moderate POAG, 46 Articles www.thelancet.com/lancetgh Vol 7 July 2019 e972 blindness (table 2) . 47 Following the National Institute for Health and Care Excellence (NICE) recommendations, 42 both costs and health state utilities were discounted at 3·5% per annum in the basecase analysis. In terms of costeffectiveness threshold, WHO defines a health intervention as being very costeffective if it costs less than the percapita gross domestic product (GDP) for a given country and as costeffective if it costs less than three times the percapita GDP. 48 The percapita GDP stratified for China's rural and urban areas was not directly available but were calculated to be $4010 and $10 800, respectively, inferred from the overall percapita national GDP ($7950), urbanisation rate, and the urbanrural ratio (2·72) of percapita disposable income.
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Outcomes
Main outcomes were incremental costutility ratios (ICURs) and incremental costeffectiveness ratios (ICERs), calculated as the difference in the total costs between the screened and unscreened cohorts, divided by the dif ference in the total QALYs between the two cohorts (ICURs) or by the years of blindness avoided between the two cohorts (ICERs). Differences were calculated as values for the screened cohort minus values for the unscreened cohort. Positive ICURs and ICERs show the incremental costs required for increasing 1 QALY or avoiding 1 year of blindness per person, respectively. Negative ICURs and ICERs (regarded as dominating) indicate that screening results in fewer costs while increasing QALYs or avoiding additional years of blindness than does no screening. A halfcycle correction 50 was applied to both costs and benefits. Reporting of methods and results conform to the Consolidated Health Economic Evaluation Reporting Standards (appendix).
51
Sensitivity analysis
To reflect the uncertainty around ICURs and ICERs, both oneway deterministic and simulated probabilistic sensitivity analyses were done. Differential discounting was used in the sensitivity analysis such that costs were discounted by 3·5% per annum and health state utilities by 1·5%. 42 The 95% CIs from the metaanalyses of glaucoma prevalence were used as the upper and lower bounds of the oneway deterministic sensitivity analysis. 52 A change of either 20% or 50% of the original values of the other parameters was used, depending on the uncertainty of the basecase parameters (appendix). 53 Additional sensitivity analyses were done by varying glaucomarelated mortality, indirect costs from blindness, and opportunistic detection rate of PAC and PAC suspect. Tornado diagrams were produced showing the five factors to which the ICURs were most sensitive. For the probabilistic sensitivity analysis, a beta distribution was assigned to prevalence and transition probabilities, a lognormal distribution to odds ratios, and a gamma distribution to cost param eters. 54 The upper and lower bounds used in the oneway probabilistic sensitivity
Values Source
Compliance with community screening Rural setting 86% Liang et al, 29 Qu et al, 30 Zhong et al, 31 Song et al, 32 Sun et al 33 Urban setting 80% He et al, 14 He et al, 34 Wang et al 35 Compliance with comprehensive hospital examination Rural setting 18·9% Wang et al 16 Urban setting 56·9% Liang et al 6 Compliance with trabeculectomy among patients with PACG and moderate and severe POAG Rural setting 80% Liang et al, 29 Qu et al, 30 Song et al, 32 Pan et al 15 Urban analysis were used to define the distribution parameters. Probabilistic uncertainty was evaluated by recalculating ICERs for 10 000 random draws from the probability distribution of each parameter. 53, 55 The percentilebased nonparametric bootstrap method 56 was used to calculate the 95% CIs for the ICURs and ICERs.
Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Results
The costutility analysis shows that programmatic screening for PACG but not POAG dominated no screening in the urban setting (table 3). In the rural setting, screening for PACG required extra financial investment but was still likely to be costeffective (ICUR $290, 95% CI −390 to 1840). POAG screening in the urban setting compared with no screening gained 1 QALY at a cost of $9060 (95% CI 4700 to 20 400), satisfying the criterion for a highly costeffective health intervention. However, POAG screening in rural areas yielded an ICUR of $15 000 (7020 to 50 500), which is approximately 3·7 times of rural GDP. When screening for both POAG and PACG simultaneously, as would usually be the case in practice, screening dominated no screening in the urban setting and the ICUR for the rural setting was $569 (17 to 4180), again suggesting that a screening programme is likely to be costeffective in both settings.
Parallel to the costutility analysis, the costeffectiveness analysis showed that screening for PACG alone resulted in fewer costs and decreased years of blindness than did no screening in the urban setting (table 3). In the rural setting, such screening would avoid 1 year of blindness at an ICER of $670 (95% CI −823 to 4570). Screening for POAG in rural areas avoided 1 year of blindness at a cost of $15 600 (6940 to 68 200), which was approximately 3·9 times the rural percapita GDP. By contrast, POAG screening in urban areas yielded an ICER of $7510 (3860 to 22 000) per year of blindness avoided and was thus likely to be costeffective. Finally, a scenario of combined PACG and POAG screening dominated no screening in the urban setting and was likely to be costeffective (ICER $1280, 95% CI −58 to 7940) in the rural setting. With such a screening programme, over the 30year time horizon investigated in the model an estimated 246 years (95% CI 63 to 628) of blindness would be avoided for every 100 000 rural residents screened and 1325 years (510 to 2828) avoided for every 100 000 urban residents screened, commencing at age 50 years. Subgroup analysis shows that combined screening in the rural setting is cost effective for all age groups (appendix). For the scenario of screening for PACG only and the combined strategy screening for both POAG and PACG, the basecase results were insensitive to uncertainty over a broad range of parameter values that we specified in the model, with all screening scenarios consistently dominant or within onetimes percapita GDP (figure). Threshold analysis showed that combined screening stopped being costeffective if screening cost per person was more than $34·2 in rural areas (11 times the actual cost of the model screening programme used in our estimates) and more than $558 in urban areas (174 times the actual cost), based on a willingnesstopay threshold of threetimes per capita GDP. For POAG screening, varying the parameters caused the ICUR to exceed the costeffectiveness threshold of threetimes percapita GDP for the rural setting but not the urban setting ( figure) . Model results were robust to several additional sensitivity analyses, varying glaucomarelated mortality, indirect costs from blindness, and the percentage of PAC and PAC suspect being opportunistically diagnosed (appendix).
Probabilistic sensitivity analysis showed that the base case ICUR and ICER were robust to randomly distributed parameters (appendix). PACG screening in rural areas dominated no screening in 18·9% of the simulations and did not dominate yet remained costeffective in the remaining 81·1%. Likewise, in the urban setting, PACG screening dominated no screening in 89·3% of simulations and was costeffective in the remaining 10·7%. Screening for POAG but not PACG was unlikely to be costeffective in the rural setting because the ICUR exceeded the costeffectiveness criterion of threetimes percapita GDP in 76·4% of simulations. By contrast, there was only 0·3% chance that screening in urban areas for POAG was not costeffective. Finally, when both POAG and PACG were simultaneously screened, screening rural and urban residents was costeffective in 99·9% and 100·0% of simulations, respectively. In both rural and urban settings, more frequent screening avoided more years of blindness (table 4). In the base case, the best scenario was annual screening, which yielded the largest health benefits with required additional costs within the WHO very costeffective threshold (table 4) . When compliance with screening, laser, and medical treatments was assumed to be perfect, annual screening in rural areas was close to the cost effective threshold and screening every 2 years was the best strategy (table 4) . By contrast, annual screening in urban areas might still be consistently costeffective, even with perfect compliance.
Discussion
Our study suggests that combined screening for POAG and PACG in China is likely to be costeffective, apparently due to the relatively low costs of screening, particularly labour costs, and the high risk of blindness in untreated cases, particularly those with PACG. Such screening in China is likely to fulfil WHO's criteria 57 for population screening: the natural history of glaucoma is adequately understood, early asymptomatic glaucoma stages are recognisable, screening is acceptable to the population, labour costs are low, and facilities for diagnosis and treatment are reasonably available.
We compared our results with previous studies. Our finding that a hypothetical screening for POAG (but not PACG) for individuals aged 50 years or older is not costeffective in rural areas accords with studies on Europeanderived populations where POAG is by far the most prevalent form of glaucoma. For instance, the incremental cost of 1 QALY gained by a POAG screening programme in Finland was found to be $38 300, which fell below the costeffectiveness threshold. 9 However, due to uncertainty in the prevalence of glaucoma, the probabilistic sensitivity analysis of this result showed that screening might not be costeffective in 29% of simulated cases. Screening for POAG in the UK resulted in an ICER above the threshold of £30 000 ($39 800) over a broad range of assumed POAG prevalences (1% to 10%). 7 This result might have been due to a combination of higher screening costs and lower savings in a highresource environment where POAG-the type less likely to lead to blindness-predominates and many patients would be detected in nonscreening settings such as during routine glasses checks. In a more recent study 8 on the worth of doing a randomised controlled trial on glaucoma screening in the UK, it was found to be unlikely to be worthwhile and resulted in an ICER that was three to four times the NICE recommended threshold. In the USA, routine patientinitiated ophthalmologic assess ments might be costeffective ($46 000 per QALY) but the results were sensitive to assumptions. 58 As a result of this evidence, multiple bodies of academics, policy makers, and programme planners, including the US Preventive Healthcare Task Force, 59 the Royal College of Ophthal mologists, 60 and the American Academy of Ophthalmology, 61 have concluded either that glaucoma screening is not costeffective or that evidence is insufficient to conclude on its costeffectiveness. None of these policy statements has recommended glaucoma screening in the general population. Regarding glaucoma screening in lowerincome and middleincome countries, a populationbased screening programme has been shown to be costeffective in India. 13 However, this analysis used a static decisionanalytic model that was primarily concerned with onetime treatment costs and thus it was not possible to consider lifetime costs, nor the transitions among different glaucomatous states, as rigorously as in the present study.
Our finding in a careful and well informed analysis that glaucoma screening is costeffective in a large country like China is of potentially great importance to policy makers and programme planners. The published literature is in wide agreement that glaucoma screening is generally not costeffective, [7] [8] [9] but this is based on assumptions (eg, labour costs of screening are high, risk of blindness without screening is only moderate due to a reasonably accessible healthcare system) that apply far better in high resource settings than lowincome and middleincome countries such as China, where around 80% of the global burden of glaucoma blindness falls. Our article challenges this by looking carefully at a well documented screening programme in China, complemented by the fairly complete literature on glaucoma epidemiology that exists in China. We feel this novel finding in China might result from a combination of lower screening costs and higher risk of eventual blindness in the absence of such programmes in the Chinese setting compared with high income countries. It is also likely that the greater cost effectiveness of screening for PACG, which is far more prevalent in China than in Europeanderived populations, plays an important role.
Thus, results from our models are more likely to be applicable where labour costs are lower and risk of blindness in untreated people is especially high-eg, in lowincome and middleincome countries, and especially those settings where highly blinding forms of glaucoma (PACG in east Asia and POAG in Africanderived populations in subSaharan Africa and the Caribbean) are prevalent. Regarding the necessity of expensive technology for successful screening, which might present a barrier in such settings, we deliberately omitted consideration of costly approaches such as visual field analysers, gonioscopy lenses, and nerve fibre layer analysis to posit a screening model with broader appli cability. The approaches modelled here are likely to be particularly relevant in Asia, where it is estimated that 61% of people living with glaucoma globally reside, and where costeffectiveness of glaucoma screening has not been widely examined. 1 Due to low expected compliance in China with hospital referrals from screening and with medical and laser therapies, we found in both rural and urban settings that each additional screening had the potential to identify additional people with earlystage glaucoma, and that more frequent, annual screening was the best strategy. However, when adherence was assumed to be perfectan unlikely assumption in view of the extensive literature-annual screening was unnecessary and screening every 2 years became the optimal strategy. With inadequate knowledge of glaucoma, patients and doctors in China generally perceive no need for comprehensive examinations to detect asymptomatic disease. 62 Available evidence suggests that offering free examinations can improve acceptance of comprehensive examinations among asymptomatic patients in rural China. 63 Full coverage of such examinations under the national health insurance system could assist with opportunistic, clinic based case detection of glaucoma. However, supporting broadbased population screening would require a substantial financial commitment from the government, which further research in this area might help to promote.
Our study has various strengths. To our knowledge, it is the first to analyse the costeffectiveness of glaucoma screening in a lowincome or middleincome country on the basis of a temporally explicit Markov model. Costs of screening and treatment were adopted from actual screening programmes and healthcare facilities in China. Our analysis employed prevalence and transition probability estimates based on the globally recognised ISGEO classification system and a careful review of the published literature. Our policyrelevant conclusions about the costeffectiveness of glaucoma screening differ substantially from much of the existing literature, especially studies in highresource countries, due to China's unique characteristics, including relatively low screening costs and high probability of eye damage among unscreened persons, especially those with PACG.
A limitation of our study is that gaps in the existing literature required us to base some transition probabilities among health states in our Markov model on non Chinese data, leading to potential inaccuracies. Also, our analysis was not informed by prospective data from a randomised controlled trial. The use of the WHO cost effectiveness threshold for cost per year of blindness avoided is consistent with previous studies, but it is unclear whether the WHO thresholds are generalisable to diseasespecific outcomes or QALYs. 9 The rural-urban comparison was done for illustrative purposes because the rural and urban GDP were calculated from overall GDP adjusted for income disparity in both settings. Although screening in urban areas might seem more costeffective than in rural areas, such screening should be offered to both rural and urban residents for equity reasons. Further, we did not stratify our analyses by sex. Neither was the costeffectiveness of different screening strategies compared in our study. In the absence of Chinese data on compliance with glaucoma medications, we based our estimates on studies of other chronic conditions, such as diabetic retinopathy and hypertension.
Because adherence to hospital examinations and medical and laser therapies is low in China, 6, 16, 64 there is substantial room for future studies to investigate the potential effects on adherence of various behavioural, economic, and educational interventions.
In conclusion, combined population screening for POAG and PACG among Chinese adults aged 50 years or older is likely to be costeffective in both rural and urban settings. Our findings were insensitive to variations across a wide range of input parameters and were robust in the probabilistic sensitivity analyses. These results are more likely to be applicable in other settings where labour costs are low, highly blinding forms of glaucoma are prevalent, and opportunistic detection rates are low. A sustainable model might be for Chinese hospitals to offer free glaucoma examinations to residents living in local villages and communities that, under present funding arrange ments, could increase the number of glaucoma inpatients and in turn increase their profits. Future studies should investigate the effectiveness of interventions among screened people to improve their compliance with hospital examination and acceptance of definitive care.
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